CTIM-76

PHILADELPHIA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced a poster regarding the Company’s clinical asset, CTIM-76, a Claudin 6 x CD3 bispecific antibody will be presented at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting, being held November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX. Presentation Details: Title:Determination of first in human dose of the T cell-redirecting bispecific antibody CTIM-76 targeting Claudin 6Authors:Kelly Byrnes-Blake, Ed Calamai, Stanley Roberts, Eric ButzAbstract Number:1288Date and Time:Saturday, November 9, 2024, 9:00a.m. CDTLocation:Exhibit Halls AB For more information and to view the abstract, visit the SITC 39th Annual Meeting website. About CTIM-76CTIM-76 is a CLDN6 x CD3 T cell engaging bispecific antibody. CLDN6 is enriched in a wide range of solid tumors, including ovarian, endometrial, lung, gastric, and testicular. Preclinical research suggests the potential for convenient dosing with low immunogenicity risk and scalable manufacturing to address the significant number of patients who are potentially eligible for CTIM-76 therapy. About Context Therapeutics®Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 bispecific antibody, CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn. Forward-looking StatementsThis press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,” “look forward,” “plan,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the ability of the Company, its employees and certain SITC presenters to participate in and present at conferences, (ii) the potential benefits, characteristics, safety and side effect profile of our product candidates, and (iii) the likelihood data will support future development. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we therefore cannot assure you that our plans, intentions, expectations, or strategies will be attained or achieved. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise. Investor Relations Contact:Jennifer Minai-AzaryChief Financial OfficerContext Therapeutics Inc.IR@contexttherapeutics.com

Context is paying BioAtla $11 million upfront for licensing rights to the bispecific, plus up to $122.5 million in milestone payments. Context Therapeutics is building up its bank of bispecific antibody candidates. The Philadelphia-based company is paying $11 million upfront for a T-cell engaging antibody from BioAtla, according to a Sept. 23 SEC filing.BioAtla is also eligible to receive $4 million in near-term milestones and $118.5 million in additional milestone payments as well as tiered royalties on net sales, according to the filing.“We believe this transaction marks the first of multiple collaborations, including a targeted collaboration for one of our phase 2 assets over the coming months, thereby increasing shareholder value through non-dilutive means,” BioAtla CEO, chair and co-founder Jay Short, Ph.D., said in a Sept. 23 release. Context’s new asset is BA3362, a bispecific that binds to Nectin-4 on tumor cells and CD3 on T cells, galvanizing the T cells to attack the cancer.Under the terms of the deal, Context has an exclusive, global license to develop, manufacture and commercialize BA3362 and will take on and fund all development and commercialization activities, the companies said in the release.“This transaction is consistent with our focus on building a pipeline of TCE assets through strategic in-licensing or acquisition,” Context CEO Martin Lehr said in the release. “Nectin-4 is a priority target for Context given the target’s high prevalence in solid tumors and the unmet need to address potential resistance to Nectin-4 antibody-drug conjugates. We identified BioAtla's Nectin-4 TCE antibody as a potentially best-in-class asset.” BA3362, now renamed CT-202, is joining two other bispecifics already moving through Context’s pipeline. CTIM-76, which targets claudin-6, and CT-95, which binds mesothelin, are set to be dosed in the first patients of phase 1 trials later this year and early next year, respectively.Context plans to apply for an investigational new drug (IND) application for CT-202 in mid-2026 and expects their cash runway to last them through the phase 1 trials and operations into 2027, according to the filing.